Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Oncoimmunology

Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D.
PMID: 23170251
Oncoimmunology. 2012 Oct 01;1(7):1027-1037. doi: 10.4161/onci.21284.

Mice with an impaired Type I interferon (IFN) signaling (IFNAR1- and IFNβ-deficient mice) display an increased susceptibility toward v-ABL-induced B-cell leukemia/lymphoma. The enhanced leukemogenesis in the absence of an intact Type I IFN signaling is caused by alterations within...

Cite
Mizutani T, Neugebauer N, Putz EM, et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology. 2012;1(7):1027-1037doi: 10.4161/onci.21284.
Mizutani, T., Neugebauer, N., Putz, E. M., Moritz, N., Simma, O., Zebedin-Brandl, E., Gotthardt, D., Warsch, W., Eckelhart, E., Kantner, H. P., Kalinke, U., Lienenklaus, S., Weiss, S., Strobl, B., Müller, M., Sexl, V., & Stoiber, D. (2012). Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology, 1(7), 1027-1037. https://doi.org/10.4161/onci.21284
Mizutani, Tatsuaki, et al. "Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance." Oncoimmunology vol. 1,7 (2012): 1027-1037. doi: https://doi.org/10.4161/onci.21284
Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology. 2012 Oct 01;1(7):1027-1037. doi: 10.4161/onci.21284. PMID: 23170251; PMCID: PMC3494617.
Copy Download .nbib Format: NLM
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Frontiers in pharmacology

Vella Bonanno P, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, Bucsics A, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Eriksson I, Fürst J, Gad M, Greičiūtė-Kuprijanov I, van der Graaff M, Gulbinovic J, Jones J, Joppi R, Kalaba M, Laius O, Langner I, Mardare I, Markovic-Pekovic V, Magnusson E, Melien O, Meshkov DO, Petrova GI, Selke G, Sermet C, Simoens S, Schuurman A, Ramos R, Rodrigues J, Zara C, Zebedin-Brandl E, Haycox A.
PMID: 28878667
Front Pharmacol. 2017 Aug 23;8:497. doi: 10.3389/fphar.2017.00497. eCollection 2017.

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not...

Cite
Vella Bonanno P, Ermisch M, Godman B, et al. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Front Pharmacol. 2017;8:497doi: 10.3389/fphar.2017.00497.
Vella Bonanno, P., Ermisch, M., Godman, B., Martin, A. P., Van Den Bergh, J., Bezmelnitsyna, L., Bucsics, A., Arickx, F., Bybau, A., Bochenek, T., van de Casteele, M., Diogene, E., Eriksson, I., Fürst, J., Gad, M., Greičiūtė-Kuprijanov, I., van der Graaff, M., Gulbinovic, J., Jones, J., Joppi, R., Kalaba, M., Laius, O., Langner, I., Mardare, I., Markovic-Pekovic, V., Magnusson, E., Melien, O., Meshkov, D. O., Petrova, G. I., Selke, G., Sermet, C., Simoens, S., Schuurman, A., Ramos, R., Rodrigues, J., Zara, C., Zebedin-Brandl, E., & Haycox, A. (2017). Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Frontiers in pharmacology, 8497. https://doi.org/10.3389/fphar.2017.00497
Vella Bonanno, Patricia, et al. "Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation." Frontiers in pharmacology vol. 8 (2017): 497. doi: https://doi.org/10.3389/fphar.2017.00497
Vella Bonanno P, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, Bucsics A, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Eriksson I, Fürst J, Gad M, Greičiūtė-Kuprijanov I, van der Graaff M, Gulbinovic J, Jones J, Joppi R, Kalaba M, Laius O, Langner I, Mardare I, Markovic-Pekovic V, Magnusson E, Melien O, Meshkov DO, Petrova GI, Selke G, Sermet C, Simoens S, Schuurman A, Ramos R, Rodrigues J, Zara C, Zebedin-Brandl E, Haycox A. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Front Pharmacol. 2017 Aug 23;8:497. doi: 10.3389/fphar.2017.00497. eCollection 2017. PMID: 28878667; PMCID: PMC5572364.
Copy Download .nbib Format: NLM
Targeting PI3Kδ: One man's meat is another man's poison.

Oncoimmunology

Prchal-Murphy M, Putz EM, Freissmuth M, Sexl V, Zebedin-Brandl E.
PMID: 23482629
Oncoimmunology. 2013 Jan 01;2(1):e22272. doi: 10.4161/onci.22272.

We have recently uncovered the indispensable role of phosphoinositide-3-kinase δ (PI3Kδ) at different stages of the canonical killing pathway of cytotoxic T lymphocytes (CTLs). The interception of PI3Kδ-conveyed signals has been considered a valuable therapeutic strategy in oncology. However,...

Cite
Prchal-Murphy M, Putz EM, Freissmuth M, et al. Targeting PI3Kδ: One man's meat is another man's poison. Oncoimmunology. 2013;2(1):e22272doi: 10.4161/onci.22272.
Prchal-Murphy, M., Putz, E. M., Freissmuth, M., Sexl, V., & Zebedin-Brandl, E. (2013). Targeting PI3Kδ: One man's meat is another man's poison. Oncoimmunology, 2(1), e22272. https://doi.org/10.4161/onci.22272
Prchal-Murphy, Michaela, et al. "Targeting PI3Kδ: One man's meat is another man's poison." Oncoimmunology vol. 2,1 (2013): e22272. doi: https://doi.org/10.4161/onci.22272
Prchal-Murphy M, Putz EM, Freissmuth M, Sexl V, Zebedin-Brandl E. Targeting PI3Kδ: One man's meat is another man's poison. Oncoimmunology. 2013 Jan 01;2(1):e22272. doi: 10.4161/onci.22272. PMID: 23482629; PMCID: PMC3583912.
Copy Download .nbib Format: NLM
Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria.

Frontiers in pharmacology

Kossmeier M, Themanns M, Hatapoglu L, Kogler B, Keuerleber S, Lichtenecker J, Sauermann R, Bucsics A, Freissmuth M, Zebedin-Brandl E.
PMID: 34483937
Front Pharmacol. 2021 Aug 13;12:726758. doi: 10.3389/fphar.2021.726758. eCollection 2021.

No abstract available.

Cite
Kossmeier M, Themanns M, Hatapoglu L, et al. Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria. Front Pharmacol. 2021;12:726758doi: 10.3389/fphar.2021.726758.
Kossmeier, M., Themanns, M., Hatapoglu, L., Kogler, B., Keuerleber, S., Lichtenecker, J., Sauermann, R., Bucsics, A., Freissmuth, M., & Zebedin-Brandl, E. (2021). Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria. Frontiers in pharmacology, 12726758. https://doi.org/10.3389/fphar.2021.726758
Kossmeier, Michael, et al. "Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria." Frontiers in pharmacology vol. 12 (2021): 726758. doi: https://doi.org/10.3389/fphar.2021.726758
Kossmeier M, Themanns M, Hatapoglu L, Kogler B, Keuerleber S, Lichtenecker J, Sauermann R, Bucsics A, Freissmuth M, Zebedin-Brandl E. Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria. Front Pharmacol. 2021 Aug 13;12:726758. doi: 10.3389/fphar.2021.726758. eCollection 2021. PMID: 34483937; PMCID: PMC8414520.
Copy Download .nbib Format: NLM
Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity.

Oncoimmunology

Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V.
PMID: 27757297
Oncoimmunology. 2016 May 19;5(9):e1186314. doi: 10.1080/2162402X.2016.1186314. eCollection 2016.

STAT1 is an important regulator of NK cell maturation and cytotoxicity. Although the consequences of

Cite
Putz EM, Majoros A, Gotthardt D, et al. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncoimmunology. 2016;5(9):e1186314doi: 10.1080/2162402X.2016.1186314.
Putz, E. M., Majoros, A., Gotthardt, D., Prchal-Murphy, M., Zebedin-Brandl, E. M., Fux, D. A., Schlattl, A., Schreiber, R. D., Carotta, S., Müller, M., Gerner, C., Decker, T., & Sexl, V. (2016). Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncoimmunology, 5(9), e1186314. https://doi.org/10.1080/2162402X.2016.1186314
Putz, Eva Maria, et al. "Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity." Oncoimmunology vol. 5,9 (2016): e1186314. doi: https://doi.org/10.1080/2162402X.2016.1186314
Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncoimmunology. 2016 May 19;5(9):e1186314. doi: 10.1080/2162402X.2016.1186314. eCollection 2016. PMID: 27757297; PMCID: PMC5048756.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries